NutriDex

The Supplement Research Compendium
🧬

Nicotinamide Riboside (NR)

An NAD+ precursor that reliably raises NAD+ but has yet to prove durable clinical benefits.

Preliminary evidence ⏳Longevity

✚ Updated · How we grade evidence

Evidence tier
Preliminary
Research weight
Citations
20 verified / 20
Classification
Longevity
❝
What the evidence says. Early or small human trials; promising but not yet conclusive.

What is Nicotinamide Riboside (NR)?

Nicotinamide Riboside (NR) is a longevity supplement used for reliably and dose-dependently raises whole-blood nad+ levels in humans, confirming target engagement. NutriDex grades the human evidence as Preliminary. Nicotinamide riboside (NR) is a form of vitamin B3 that the body converts into nicotinamide adenine dinucleotide (NAD+), a coenzyme central to energy metabolism and cellular repair that declines with age. Multiple randomized controlled trials confirm that oral NR reliably and dose-dependently raises blood NAD+ levels and is well tolerated, establishing clear biological target engagement. However, this NAD+ boost has not yet translated into robust clinical benefits: trials in obese, insulin-resistant men showed no improvement in insulin sensitivity, and a trial in peripheral artery disease found no improvement in walking performance. The most promising—but still preliminary—human signal is a modest reduction in systolic blood pressure and improved endothelial function in midlife and older adults with elevated blood pressure. Overall, NR is a credible NAD+ precursor whose marketed anti-aging, metabolic, and cardiovascular benefits remain largely unproven in humans and require larger, longer trials.

Purported Benefits

✓Reliably and dose-dependently raises whole-blood NAD+ levels in humans, confirming target engagement
✓Consistently well tolerated across doses up to 1000-3000 mg/day with only mild adverse effects
✓Preliminary signals of lowered systolic blood pressure and improved vascular endothelial function in adults with above-normal blood pressure
✓May modestly shift body composition and tissue metabolite profiles, though clinical relevance is unclear

Evidence by outcome

The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.

OutcomeEvidenceEffectStudies
Raises whole-blood NAD+ levelsMultiple RCTs show reliable dose-dependent NAD+ rise (up to several-fold); clear target engagement. Strong ↑ benefit · large 4
Safety / tolerabilityWell tolerated up to 3000 mg/day across trials including Parkinson's and HFrEF, only mild adverse effects. Strong ↑ benefit · large 4
Systolic BP / endothelial function (elevated-BP adults)Pooled and crossover RCTs suggest ~8-9 mmHg SBP drop in those with high baseline BP; needs larger confirmation. Preliminary ↑ benefit · moderate 2
Insulin sensitivity / glucose metabolismRCT in obese men found no improvement; NAD-precursor MA even showed slightly raised fasting glucose. Moderate — no effect · negligible 2
Walking performance in peripheral artery diseaseNICE trial primary endpoint non-significant overall; a modest 6-min-walk gain emerged only in adherent participants. Mixed ↔ mixed · small 2
Muscle mass / strength / gait in older adultsTwo 2025 MAs found no improvement in muscle index, grip strength, gait speed, or chair-stand. Moderate — no effect · negligible 2

Dosing & Compounds

Typical Dose
250–1000 mg/day orally (trials have used up to 2000–3000 mg/day); commonly 300 mg once daily for general use
Active Compounds
Nicotinamide riboside chloride (Niagen)Nicotinamide adenine dinucleotide (NAD+) — the downstream metabolite it elevates

Safety & Cautions

Generally well tolerated; most common adverse effects are mild headache, flushing or feelings of warmth, gastrointestinal discomfort, nausea, and fatigue. Long-term safety beyond ~1 year and at high doses is not well established. Because NR raises NAD+ and is metabolized partly to nicotinamide, theoretical concerns exist about effects on methylation balance and, at very high intakes, on cancer cell metabolism—so it should be avoided or used only under medical supervision by people with active or prior cancer. Safety has not been established in pregnancy or breastfeeding, so these groups should avoid it. People with kidney or liver disease, those on multiple medications, or anyone with a serious medical condition should consult a clinician first, as data on drug interactions are limited. NR is not a substitute for proven treatments for hypertension, diabetes, or cardiovascular disease. Educational only — always check with your doctor or pharmacist before combining Nicotinamide Riboside (NR) with any medicine.

Key Studies ★ 20 studies

Meta-analysis Yang 2025 (J Cachexia Sarcopenia Muscle) ✓ Full text
Pooled analysis of 10 RCTs in adults over 60 found NMN and nicotinamide riboside produced no significant improvement in muscle mass index, handgrip strength, gait speed, or chair-stand performance, with NR benefit limited to 6-minute walk distance in PAD.
Meta-analysis Oliveira-Cruz 2024 (NAD+ precursors, metabolic syndrome) ✓ PubMed
Systematic review/meta-analysis of 19 RCTs (PRISMA, RoB2, GRADE): NAD+ precursor supplementation significantly reduced plasma total cholesterol and triglycerides, but did not significantly affect other metabolic syndrome parameters; GRADE quality very low to low.
Meta-analysis Prokopidis 2025 (NMN/NR & skeletal muscle) ✓ PubMed
Systematic review/meta-analysis of RCTs in adults (mean age >60): neither NR nor NMN significantly improved skeletal muscle index, handgrip strength, gait speed, or chair-stand time; current evidence does not support NR/NMN for preserving muscle mass or function.
Meta-analysis Zhong 2022 (NAD+ precursors, glucose & lipids) ✓ PubMed
Meta-analysis of 40 trials (n=14,750): NAD+ precursors significantly lowered TG (SMD -0.35), TC (SMD -0.33) and LDL (SMD -0.38) and raised HDL (SMD +0.66), but increased fasting glucose (SMD +0.27); lipid effects driven mainly by nicotinic acid, with little benefit in healthy people.
Systematic review systematic review ✓ Source
Across diverse clinical conditions, NAD precursors including NR were generally safe and effective at raising NAD+, but evidence for disease-specific clinical efficacy was inconsistent.
RCT Martens 2026 ✓ PubMed
Phase-II randomized controlled pilot of nicotinamide riboside in older adults with amnestic mild cognitive impairment.
RCT Vrijsen 2025 (eClinicalMedicine) ✓ PubMed
In 58 long-COVID patients, nicotinamide riboside raised blood NAD+ 2.6-3.1 fold but showed no significant between-group benefit on cognition, fatigue, sleep, anxiety, or depression vs placebo.
RCT McDermott 2024 NICE trial (Nat Commun) ✓ PubMed
In 90 patients with peripheral artery disease, 6 months of nicotinamide riboside improved 6-minute walk distance by 17.6 m vs placebo, rising to 31.0 m among participants with at least 75% adherence.
RCT Magnetic Resonance in Medicine 2024 ✓ Full text
In 9 healthy volunteers, a single 900 mg oral dose of nicotinamide riboside increased in vivo cerebral NAD+ measured by 7T MR spectroscopy from 0.392 to 0.458 mM (about 16%, p<0.001).
RCT Berven 2023 (NR-SAFE Parkinson's RCT) ✓ PubMed
Phase I randomized double-blind placebo-controlled trial, 20 PD patients, NR 1500 mg twice daily (3000 mg/day) x4 weeks: no moderate/severe adverse events; well tolerated; blood NAD+ rose up to 5-fold. Mild transient homocysteine rise without depleting the methyl-donor pool; supports extending dosing to 3000 mg/day in phase II.
RCT Trammell & Brenner (NR PK trial) 2016 ✓ PubMed
First-in-human pharmacokinetic clinical trial: single oral NR doses of 100, 300 and 1000 mg produced dose-dependent increases in the blood NAD+ metabolome (whole-blood NAD+ rose up to ~2.7-fold), establishing NR as orally bioavailable and identifying NAAD as a sensitive biomarker of NAD+ repletion; no safety concerns.
RCT Martens 2018 (NR crossover RCT) ✓ PubMed
2x6-week randomized double-blind placebo-controlled crossover in 30 healthy middle-aged/older adults: NR 1000 mg/day was well tolerated and raised blood NAD+ ~60%. Exploratory signals suggested reduced systolic BP (~-3 mmHg overall; ~-9 mmHg in those with elevated baseline SBP) and lower aortic stiffness, motivating larger BP trials.
RCT n=40 obese men, 12 wk ✓ PubMed
NR 2000 mg/day was safe but did not improve insulin sensitivity or whole-body glucose metabolism in obese, insulin-resistant men versus placebo.
RCT n=118 (pooled), ~3 mo ✓ PubMed
NR 1000 mg/day lowered casual systolic blood pressure by roughly 8–9 mmHg and improved vascular endothelial function in midlife/older adults with above-normal baseline systolic BP.
RCT n=90, 6 mo ✓ Source
In the NICE trial, NR (with or without resveratrol) did not significantly improve 6-minute walk distance versus placebo in patients with peripheral artery disease.
RCT (safety) high-dose safety trial ✓ Full text
NR up to 3000 mg/day for several weeks in Parkinson's disease patients was safe and well tolerated with no moderate or severe attributable adverse events.
RCT (safety) n=30, 12 wk ✓ Full text
NR 2000 mg/day was safe, well tolerated, and significantly raised whole-blood NAD+ in patients with heart failure with reduced ejection fraction.
Review Pandolfi 2026 ✓ PubMed
Review of NAD+ biology and supplementation, from mechanisms to clinical perspectives.
Review Somers 2026 ✓ PubMed
NAD Metabolism in Acute Myeloid Leukaemia: Biological Rationale and Therapeutic Opportunities
Review Shokr 2026 ✓ PubMed
The gut-brain-mitophagy axis: Urolithin A as a transcriptional activator of Parkin in Alzheimer's and Parkinson's diseases
20 sources cited · 20 verified Search all studies on PubMed ↗

Common questions about Nicotinamide Riboside (NR)

What is Nicotinamide Riboside (NR) used for?

Nicotinamide Riboside (NR) is most often taken for Reliably and dose-dependently raises whole-blood NAD+ levels in humans, confirming target engagement, Consistently well tolerated across doses up to 1000-3000 mg/day with only mild adverse effects, Preliminary signals of lowered systolic blood pressure and improved vascular endothelial function in adults with above-normal blood pressure, May modestly shift body composition and tissue metabolite profiles, though clinical relevance is unclear. An NAD+ precursor that reliably raises NAD+ but has yet to prove durable clinical benefits.

Does Nicotinamide Riboside (NR) work — what does the evidence say?

Preliminary evidence. Early or small human trials; promising but not yet conclusive. Nicotinamide riboside (NR) is a form of vitamin B3 that the body converts into nicotinamide adenine dinucleotide (NAD+), a coenzyme central to energy metabolism and cellular repair that declines with age. Multiple randomized controlled trials confirm that oral NR reliably and dose-dependently raises blood NAD+ levels and is well tolerated, establishing clear biological target engagement. However, this NAD+ boost has not yet translated into robust clinical benefits: trials in obese, insulin-resistant men showed no improvement in insulin sensitivity, and a trial in peripheral artery disease found no improvement in walking performance. The most promising—but still preliminary—human signal is a modest reduction in systolic blood pressure and improved endothelial function in midlife and older adults with elevated blood pressure. Overall, NR is a credible NAD+ precursor whose marketed anti-aging, metabolic, and cardiovascular benefits remain largely unproven in humans and require larger, longer trials.

What is the typical dose of Nicotinamide Riboside (NR)?

250–1000 mg/day orally (trials have used up to 2000–3000 mg/day); commonly 300 mg once daily for general use

Is Nicotinamide Riboside (NR) safe? Any cautions or side effects?

Generally well tolerated; most common adverse effects are mild headache, flushing or feelings of warmth, gastrointestinal discomfort, nausea, and fatigue. Long-term safety beyond ~1 year and at high doses is not well established. Because NR raises NAD+ and is metabolized partly to nicotinamide, theoretical concerns exist about effects on methylation balance and, at very high intakes, on cancer cell metabolism—so it should be avoided or used only under medical supervision by people with active or prior cancer. Safety has not been established in pregnancy or breastfeeding, so these groups should avoid it. People with kidney or liver disease, those on multiple medications, or anyone with a serious medical condition should consult a clinician first, as data on drug interactions are limited. NR is not a substitute for proven treatments for hypertension, diabetes, or cardiovascular disease.

How many studies support Nicotinamide Riboside (NR)?

NutriDex cites 20 sources for Nicotinamide Riboside (NR), graded "Preliminary".

Cite this page
APA

Peh, D. (2026). Nicotinamide Riboside (NR): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 16 Sept 2026, from https://nutridex.info/s/nicotinamide-riboside

BibTeX
@misc{nutridex_nicotinamide_riboside,
  author       = {Peh, Daryl},
  title        = {Nicotinamide Riboside (NR): Benefits, Dosage, Side Effects \& Evidence},
  year         = {2026},
  howpublished = {NutriDex --- The Supplement Research Compendium},
  url          = {https://nutridex.info/s/nicotinamide-riboside},
  note         = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-09-16}
}

For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.

← Back to the full dex · All substances